Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Naval G. Daver, MD

home / authors / naval-g-daver-md

Articles


Unmet Needs for Patients With AML

Unmet Needs for Patients With AML

Naval G. Daver, MD
January 3rd 2024

Naval G. Daver, MD, discusses the unmet needs that still exist in the treatment of acute myeloid leukemia.


Transplants in the AML Treatment Landscape

Transplants in the AML Treatment Landscape

Naval G. Daver, MD
January 2nd 2024

Naval G. Daver, MD, discusses how stem cell transplants factor into the current treatment landscape of acute myeloid leukemia.


Shifts the the AML Treatment Landscape

Shifts the the AML Treatment Landscape

Naval G. Daver, MD
December 28th 2023

Naval Daver, MD, discusses the evolution in the treatment of acute myeloid leukemia for both older and younger patient populations.


Magrolimab Shows Promise in MDS and AML

Magrolimab Shows Promise in MDS and AML

Naval G. Daver, MD
October 4th 2022

Naval G. Daver, MD, discusses the latest research on magrolimab, a CD47 monoclonal antibody, for patients with acute myeloid leukemia and myelodysplastic syndrome.


Exploring the Data for AML Treated With Magrolimab and Azacitidine

Exploring the Data for AML Treated With Magrolimab and Azacitidine

Naval G. Daver, MD
July 17th 2020

Naval G. Daver, MD, discusses a phase 1b trial evaluating the efficacy of margolimab and azacitidine combination for patients with acute myeloid leukemia.


Second-Generation FLT3 Inhibitors Produce Higher Response Rates in AML

Second-Generation FLT3 Inhibitors Produce Higher Response Rates in AML

Naval G. Daver, MD
July 23rd 2019

Naval G. Daver, MD, discusses how the efficacy compares between first- and second-generation FLT3 inhibitors in acute myeloid leukemia.


Combination Checkpoint Therapy Gains Ground in AML and MDS

Combination Checkpoint Therapy Gains Ground in AML and MDS

Naval G. Daver, MD
November 9th 2017

Checkpoint-based immune therapies have revolutionized the therapy of solid tumors by achieving breakthrough improvements in melanoma, lung cancer, renal cancer, bladder cancers, and head and neck tumors, among others.

Latest Updated Articles

Myeloma Research Sees Transformation Following ODAC Support For MRD End Point
Published: May 20th 2025 | Updated: June 4th 2025
Myeloma Research Sees Transformation Following ODAC Support For MRD End Point
One Year After ODAC Decision: Myeloma Studies Move to Adopt MRD End Point
Published: May 19th 2025 | Updated: May 20th 2025
One Year After ODAC Decision: Myeloma Studies Move to Adopt MRD End Point
ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Mismatched Unrelated Donors and PTCy: Better HSCT Outcomes, Expanded Access
Published: June 23rd 2025 | Updated: June 25th 2025
Mismatched Unrelated Donors and PTCy: Better HSCT Outcomes, Expanded Access
Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC
Published: June 19th 2025 | Updated: June 25th 2025
Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC
About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.